Basal Cell Carcinoma (BCC)
Basal cell carcinoma (BCC) predominantly develops in sun-exposed regions of the skin, such as the face, scalp, neck, and shoulders. Our esteemed company specializes in pioneering drug and therapy development services specifically tailored for BCC.
Overview of Basal Cell Carcinoma
Basal cell carcinoma (BCC), also known as basal cell skin cancer or basal cell cancer, is a highly prevalent form of skin cancer. Each year in the United States, approximately 3.6 million cases occur annually. This particular type of cancer originates from the basal cells, which are located in the outermost layer of the skin known as the epidermis. While BCC rarely spreads to other parts of the body, it can still cause considerable damage if left untreated.
Pathogenesis of Basal Cell Carcinoma
Prolonged exposure to ultraviolet (UV) radiation from the sun is the primary culprit behind the development of basal cell carcinoma (BCC). The DNA of basal cells becomes damaged as a result of chronic exposure to UV radiation, ultimately leading to the formation of cancerous cells. Additional risk factors for BCC include a history of sunburns, a compromised immune system, exposure to certain chemicals, and genetic conditions such as basal cell carcinoma nevus syndrome (BCCNS).
Fig. 1 Pathological features of nodular BCC (H&E; 10×). (Fania L., et al., 2020)Molecular Characteristics of Basal Cell Carcinoma
BCC is characterized by distinct molecular changes that play a crucial role in its development. Frequent mutations in genes involved in the Hedgehog signaling pathway, including PTCH1 and SMO, have been identified in BCC. These genetic alterations result in the constant activation of the pathway, driving uncontrolled cell growth and the formation of tumors. Furthermore, modifications in other signaling pathways, such as MAPK and PI3K-AKT-mTOR, have also been implicated in the pathogenesis of BCC.
Targeted Therapy of Basal Cell Carcinoma
Targeted therapies have brought about a revolutionary change in the treatment of BCC, transforming the therapeutic landscape. Notably, two Hedgehog pathway inhibitors (HhIs), namely vismodegib and sonidegib, have received approval for the management of advanced BCC. These inhibitors specifically target the SMO protein, a critical component of the Hedgehog pathway. Studies have demonstrated remarkable response rates and durable outcomes with the use of these inhibitors, offering renewed hope for patients who may not be suitable candidates for surgery or radiotherapy. Ongoing research endeavors are focused on optimizing the use of HhIs through combination therapies and exploring their potential in the neoadjuvant setting.
Fig. 2 Therapies of BCC. (Garcovich S., et al., 2017)Our Services
At our esteemed organization, we have carved a niche in delivering comprehensive diagnostics and therapy development services specifically tailored for basal cell carcinoma (BCC). With an unwavering dedication to scientific excellence and a steadfast commitment to advancing cancer research, we have earned a trusted reputation as a reliable partner in the battle against BCC.
Therapy Development Platforms
Animal Models of Basal Cell Carcinoma
Our company's commitment to advancing BCC therapy is exemplified by our extensive preclinical research efforts. Through the development of animal models, we can simulate BCC progression and evaluate the efficacy of potential therapeutic interventions.
| Genetic Engineering Model Development | ||
| PTCH1 mutations, along with mutations in other genes within the Hedgehog (Hh) signaling pathway, are crucial for BCC development. Our company specializes in developing genetic engineering models that mimic the genetic alterations observed in human BCC. | ||
| Optional Models |
|
|
| Optional Species | Mouse, Rat, Tree Shrew, Non-human primates, Others | |
In addition, we also provide other customized animal models to meet diverse needs. If you are interested in our services, please feel free to contact us for more details and quotation information of related services.
References
- Fania L., et al." Basal cell carcinoma: from pathophysiology to novel therapeutic approaches." Biomedicines 8.11 (2020): 449.
- Garcovich S., et al. "Skin Cancer Epidemics in the Elderly as An Emerging Issue in Geriatric Oncology." Aging Dis. 2017 Oct 1;8(5):643-661.
- Dika E., et al. "Basal cell carcinoma: a comprehensive review." International Journal of Molecular Sciences 21.15 (2020): 5572.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.